Europe’s medical devices industry saw a rise of 25.64% in deal activity during June 2022, when compared with the last 12-month average, led by ResMed’s $1bn acquisition of MediFox DAN Group, according to GlobalData’s deals database.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 49 medical devices industry deals worth $2.2bn were announced for the region in June 2022, against the 12-month average of 39 deals.
Of all the deal types, venture financing saw most activity in June 2022 with 25 transactions, representing a 51.02% share for the region.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was M&A with 19 deals, followed by private equity deals with five transactions, respectively capturing a 38.8% and 10.2% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $1.14bn, while private equity and venture financing deals totalled $843.97m and $198.66m, respectively.
Europe medical devices industry deals in June 2022: Top deals
The top five medical devices deals accounted for 91.9% of the overall value during June 2022.
The combined value of the top five medical devices deals stood at $2.01bn, against the overall value of $2.2bn recorded for the month.
The top five medical devices industry deals of June 2022 tracked by GlobalData were:
1) ResMed $1bn acquisition deal with MediFox DAN Group
2) The $797.86m private equity of SPT Labtech by EQT IX Fund
3) Azenta $85.5m acquisition deal with Barkey GmbHKG
4) The $80m venture financing of Proximie by Advent Life Sciences,British Patient Capital,Eight Roads Ventures,Emerson Collective,F Prime Capital,Global ventures,Maverick Ventures Israel,Minderoo Foundation,Mubadala Investment,Questa Capital Management and SoftBank Vision Fund 2
5) Fujirebio $42.15m acquisition deal with ADx NeuroSciences
